High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.

Slides:



Advertisements
Similar presentations
The Impact of Gynecologic Pathology Diagnostic Errors on Patient Care Dana Marie Grzybicki MD, PhD Colleen M. Vrbin, BA Danielle Pirain, BS Stephen S.
Advertisements

Prostate cancer diagnosis today Mungai Ngugi. Introduction Prostate cancer remains a major problem in the world and particularly in black people who have.
DIAGNOSI E STADIAZIONE DEL CARCINOMA PROSTATICO Maurizio Brausi Direttore Urologia Ausl Modena Chairman ESOU Director Prostate Cancer Unit.
THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol.
Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.
A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.
Diagnosis of prostate cancer on needle biopsy: Current practices Medical College of Georgia 12/07/2006 Jeremy S. Miller, MD.
Grade 1 (almost) never assigned Grade 2 rarely assigned on TURP and RP (exceptionally rare on biopsy)
Prevention Strategies Rajesh G. Laungani MD Director, Robotic Urology Chairman, Prostate Cancer Center Saint Joseph’s Hospital, Atlanta.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Expectant Management of Prostate Cancer James A. Eastham, MD and Peter T. Scardino, MD June 23, 2010 Presented by: K. Witzke, DO.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Joint Hospital Surgical Grand Round 19 June 2004.
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Prostate Cancer Screening Assistant Professor Charles Chabert Men’s health Seminar Ballina April 2011 prostates.com.au.
Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
Professor Abhay Rane OBE
UOG Journal Club: January 2013
Pathology of Prostatic Enlargement
EPCA: A silver lining for early diagnosis of prostate cancer GHOLAMREZA POURMAND, MD Professor of Urology Urology Research Center Tehran University of.
RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Prostate Cancer Screening in 2013: Reports of its Death Are Greatly Exaggerated Norm D. Smith, M.D. Associate Professor Co-Director Urologic Oncology University.
Urology Update Sanofi- Aventis
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
#1003 Prostate Cancer Update October 5 to October 8 Robert R. Bahnson, MD Louis Levy Professor of Surgery Director, Division of Urology The Ohio State.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
PCa Screening New Areas of Research Francesco Montorsi Milan.
PSA Testing Importance of Multiple Markers Ian Thompson MD Department of Urology University of Texas HSC San Antonio, TX.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
A Clinical Profile of Male Health in the Bahamas “Real Men Die from Prostate Cancer” A Clinical Profile of Male Health in the Bahamas “Real Men Die from.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.
Good morning, have a nice time. What’s new about lesions of prostatic gland? By Taghreed Abd El_Sameea Ass. Prof. of pathology Faculty of Medicine Benha.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
TEMPLATE DESIGN © Negative LLETZ following severe dyskaryosis: a curious phenomenon Üçyiğit A, Jones M H, Dutta A, El.
Understanding Prostate Myths
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
PSA screening Cost Conscious Project Kristopher Huston January 2016.
Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
“Clinical and molecular effects of dietary supplements in patients with ASAP and/or multifocal HGPIN: a randomized double-blinded placebo controlled phase.
The Natural History of Benign Thyroid Nodules JAMA. 2015;313(9): doi: /jama Modulator Prof. 전숙 / R1 윤수진.
Prostate Cancer Dr .Gehan Mohamed.
Comparison of PSA Values of Prostate Cancer Patients Before, During and After Prostate Biopsy Using Gleason Score Mehmet KILINC1, Yunus Emre GOGER1, Hasan.
Nat. Rev. Urol. doi: /nrurol
What would you recommend?
Patterns of prostate cancer according to the 2005 International Society of Urological Pathology Consensus Conference on Gleason system. (Adapted with permission.
Urologist’s Impact on Extended Needle Core Prostate Biopsy Histopathologic Variables within a Single Institution Kashika G. Goyal B.S.1, Joshua J. Ebel.
Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Prostate Cancer Screening- Update
Volume 60, Issue 5, Pages (November 2011)
Volume 62, Issue 1, Pages (July 2012)
Volume 50, Issue 4, Pages (October 2006)
Rodolfo Montironi, Ming Zhou, Cristina Magi-Galluzzi, Jonathan I
Volume 62, Issue 3, Pages (September 2012)
Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer  MICHAEL R. CUPP,
Active Surveillance for Low Risk Prostate Cancer
Nat. Rev. Urol. doi: /nrurol
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Figure 4 Algorithm for when to determine PTEN
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern Tarek Bishara, MD,* Dharam M. Ramnani, MD, # Jonathan I. Epstein, MD. *Pee Dee Pathology Associates, Florence, SC; # Virginia Urology Center, Richmond, VA; and Johns Hopkins Medical Institutions, Baltimore, MD. Am J Surg Pathol · Volume 28, Number 5, May 2004

HGPIN Definition:Definition: an abnormal proliferation of prostate ducts and acini with cytologic changes similar to prostatic carcinoma Importance on needle biopsy:Importance on needle biopsy: an association with synchronous, occult prostatic adenocarcinoma

HGPIN Isolated finding on needle biopsy:Isolated finding on needle biopsy: 0.7% to 24 % (4% to 6%) Risk of carcinoma in subsequent biopsy:Risk of carcinoma in subsequent biopsy: 23% to 79% (23% to 35%, mean= 25.3%) –in a contemporary, PSA-screened population: –in a contemporary, PSA-screened population: 10% to 27% –risk of finding cancer after a benign diagnosis on needle biopsy: –risk of finding cancer after a benign diagnosis on needle biopsy: 11% to 24% (26.2%)

HGPIN Whether or not a patient should be rebiopsied based solely on an isolated HGPIN diagnosis? Will clinical factors help in predicting which patients will have prostatic carcinoma on follow-up biopsies? –DRE, serum PSA levels, and transrectal ultrasound findings

METHODS 200 cases (May 1999 ~ Sep 2002) –179 cases (89.5%) had available follow-up information –132 cases (66%) had ≥ 1 follow-up biopsy

METHODS Histological subtypes: –tufting / flat –micropapillary / cribriform Number of cores involved by HGPIN

METHODS Rebiopsied specimen –benign prostatic tissue –HGPIN –atypical glands –carcinoma

RESULTS Age: years (mean = 66.4) Interval between initial biopsy and first rebiopsy: 1 to 33 months (mean = 7) Number of prostatic cores per biopsy set: 4 to 15 –standard 6 core sextant biopsy was obtained in 59.8% of initial biopsies and 61% of follow-up biopsies

RESULTS Histologic subtypes in initial biopsies –tufting: 59.0% (115 of 195) –micropapillary: 34.3% (67 of 195) –cribriform: 6.2% (12 of 195) –flat: 0.5% (1 of 195) Extent in initial biopsies –One core: 51.5% (68 of 132) –Two or more cores: 48.5% (64 of 132)

RESULTS Diagnosis in the follow-up biopsies –Benign prostatic tissue: 45% (60 of 132) –HGPIN: 17.4% (23 of 132) –Atypical glands: 8.3% (11 of 132) –Adenocarcinoma: 28.8% (38 of 132)

RESULTS Adenocarcinoma in follow-up biopsies –incidence: 28.8% (38/132) –Interval between repeat biopsy: 2-36 months (mean=10.6) –Gleason score 5: 5.3% ( 2 of 38) 6: 89.5% (34 of 38) 7: 5.3% ( 2 of 38)

RESULTS Incidence of subsequent carcinoma –tufting / flat: 31.9% (29/91) –micropapillary / cribriform: 22.0% (9 of 41) –p = 0.244

RESULTS Incidence of subsequent carcinoma –1 core with HGPIN: 22.0% (15/68) –≥ 2 cores with HGPIN: 35.9% (23 of 64) –p = 0.078

RESULTS Adenocarcinoma in follow-up biopsies –1st follow-up biopsy: 71.1% (27 of 38) –2nd follow-up biopsy: 18.4% (7 of 38) –3rd follow-up biopsy: 10.5% (4 of 38) –4th follow-up biopsy: 2.6% (1 of 38) All had abnormal diagnoses on at least one of the previous biopsies

RESULTS Incidence of subsequent carcinoma –Benign diagnosis on the 1st follow-up biopsy (n=36): 14.3 % (2 of 14) –HGPIN on the 1st follow-up biopsy (n=25): 32.0% (8 of 25) –Small atypical glands on the 1st follow-up biopsy (n=6): 33.3% (1 of 3)

RESULTS Incidence of subsequent carcinoma –Multiple cores involved by HGPIN on the 1st follow-up biopsy: 50.0 % (8 of 16) –Only one core involved by HGPIN on the 1st follow-up biopsy: 0 % (0 of 9) –p = 0.01

RESULTS If one combined the risk of cancer on repeat biopsy for those men with either no HGPIN or one core with HGPIN on first repeat biopsy as compared with men with multiple cores of HGPIN on repeat biopsy, the result was more significant (P = 0.008).

Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma George J. Netto, MD. and Jonathan I. Epstein, MD.* Departments of Pathology, * Urology, and * Oncology, The Johns Hopkins Hospital, Baltimore, MD. Am J Surg Pathol 2006;30:1184–1188

MATERIALS & METHODS 73 cases (1994 ~ 2005) –Prostatic needle biopsy –Diagnosis of HGPIN in a minimum of 4 cores

MATERIALS & METHODS 73 cases –41 cases had at least one follow-up biopsy age: 66.8 years numbers of initial cores: 10.4 PSA: ng/mL (mean=14.1; median=8.2) –32 cases were lack of follow-up biopsy age: 68.2 years numbers of initial cores: 10.4 PSA: ng/mL (mean=3.5; median=3.3)

MATERIALS & METHODS Data of follow-up samples –Date –Nature –Frequency

MATERIALS & METHODS Diagnosis of follow-up samples –benign prostatic tissue (BPT) –HGPIN HGPIN with adjacent small atypical glands (PINATYP) –carcinoma (PCa)

MATERIALS & METHODS Statistics –STATA, College Station, TX –Student t test to assess potiential differences in age and number of cores sampled between those men with and without repeat biopsy –X 2 test to assess differences between subgroups among men who had a repeat biopsy

RESULTS Age: 66.8 years Period of follow-up: 1-41 months (mean=11) Numbers of cores on initial biopsy: 5-16 (mean=10.6; median=10) Numbers of cores on follow-up biopsy: 6-16 (mean=10.4; median=10)

RESULTS Follow-up biopsy –1 repeat biopsy: 34 p’ts –2 repeat biopsies: 3 p’ts –1 repeat biopsy followed by 1 TURP: 1 p’t –1 repeat biopsy followed by 2 TURPs: 1 p’t –1 TURP: 3 p’ts

RESULTS All but 1 of the prostate cancers were identified on the first F/U procedure All but 1 of the prostatic carcinomas were diagnosed within 2 years from the initial biopsy with 10 rendered within the first year

RESULTS Adenocarcinoma in follow-up biopsies –incidence: 39% (16/41) –time from the initial biopsy: 1-36 months (mean=10.4) –Gleason score 5: 6.3% ( 1 of 16) 6: 68.7% (11 of 16) 7: 18.8% ( 3 of 16) 9: 6.3% ( 1 of 16)

RESULTS 5 p’ts with more than 1 f/u biopsies –1st f/u biopsy (negative) --> TURP (PCa) –1st and 2nd f/u biopsies (HGPIN) –1st f/u biopsy (HGPIN) --> biopsy (PINATYP) –1st f/u biopsy (PINATYP) --> biopsy (HGPIN) –1st f/u biopsy (PINATYP) --> TURP (BPT) --> TURP (BPT)

DISCUSSION The reported likelihood of finding cancer after a diagnosis of HGPIN on needle biopsy has decreased in the contemporary era. Seven of nine large studies showed no statistically significant difference in the risk of cancer on repeat biopsy after an HGPIN diagnosis compared with rebiopsy after a benign diagnosis.

DISCUSSION Herawi M, et al. Risk of prostate cancer on re-biopsy following a diagnosis of high-grade prostatic intraepithelial neoplasia (HGPIN) is related to the number of cores sampled. J Urol. 2006;175:121–124. –In cases with 6 core biopsies for both the initial and rebiopsy, the risk of cancer after HGPIN was 14.1% (20/142) –With an initial 6 core biopsy and >8 core repeat biopsy, the risk increased to 31.9% (36/113) –With >8 core biopsy sampling for both the initial and repeat biopsies, the risk for cancer was 14.6% (37/253)

DISCUSSION Delaying the repeat biopsy allowing for a longer interval than the originally recommended 6 to 12 months Identifying a subset of HGPIN patients with a higher subsequent PCa risk

DISCUSSION Our study demonstrated a 39% likelihood of finding PCa after the initial identification of widespread (4 or more HGPIN) The 39% likelihood rate stands in significant contrast to the baseline risk (19% to 26.2%) of finding adenocarcinoma on a repeat biopsy after an initial benign diagnosis.

DISCUSSION All but 1 cases of the adenocarcinoma diagnoses were obtained at the first F/U procedure. The absolute need for a second repeat biopsy after a first negative repeat biopsy could be questioned.

SUMMARY An initial finding of HGPIN on 4 or more cores Patients older than 70 years of age Patients with a fewer numbers of cores on initial biopsy

Cia!